Brief: Kronos Bio Announces First Patient Dosed In Phase 1B/2 Clinical Trial Of Lanraplenib In Combination With Gilteritinib In Acute Myeloid Leukemia
22/08/2022 13:11
Aug 22 (Reuters) - Kronos Bio Inc KRON.O :
* KRONOS BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B/2
CLINICAL
TRIAL OF LANRAPLENIB IN COMBINATION WITH GILTERITINIB IN ACUTE
MYELOID LEUKEMIA
Source text for Eikon: ID:nGNX1jj4XZ
Further company coverage: KRON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kronos Bio
See all newsBrief: Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC Filing
Brief: Kronos Bio Inc - Enters Transition Agreement With Genentech
U.S. STOCKS ON THE MOVE - Ambarella, Dell, Nordstrom
U.S. STOCKS ON THE MOVE - Golden Ocean, Guess, Symbotic
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems